Latest News for: keros

Edit

Material Agreement (Form 8-K) (Keros Therapeutics Inc)

Public Technologies 18 Apr 2025
) Item 1.01 Entry into a Material Definitive Agreement. On April 17, 2025, Keros Therapeutics, Inc ... Disclaimer. Keros Therapeutics Inc published this content on April 18, 2025, and is solely responsible for the information contained herein ... (noodl.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Keros Therapeutics Inc)

Public Technologies 12 Apr 2025
) FORM 4. Check this box if no longer subject to Section 16 ... See Instruction 1(b) ... Washington, D.C ... 2 ... Keros Therapeutics, Inc ... Keros Therapeutics Inc published this content on April 11, 2025, and is solely responsible for the information contained herein.
Edit

Initial Statement of Beneficial Ownership (Form 3) (Keros Therapeutics Inc)

Public Technologies 12 Apr 2025
) FORM 3. UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C ... OMB Number. 3235-0104 ... 2 ... Keros Therapeutics, Inc ... Keros Therapeutics Inc published this content on April 11, 2025, and is solely responsible for the information contained herein.
Edit

Keros Therapeutics Announces Review of Strategic Alternatives

Nasdaq Globe Newswire 10 Apr 2025
LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq ... .
Edit

Keros Therapeutics Announces Review of Strategic Alternatives (Form 8-K) (Keros Therapeutics Inc)

Public Technologies 10 Apr 2025
) Keros Therapeutics Announces Review of Strategic Alternatives ... 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq ... About Keros Therapeutics, Inc.
Edit

New Listing Registration (Form 8-A12B) (Keros Therapeutics Inc)

Public Technologies 10 Apr 2025
Keros Therapeutics, Inc ... On April 9, 2025, the Board of Directors (the "Board") of Keros Therapeutics, Inc ... Certificate of Designations of Series A Junior Participating Preferred Stock of Keros Therapeutics, Inc ... KEROS THERAPEUTICS, INC.
Edit

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers (Form 8-K) (Keros Therapeutics Inc)

Public Technologies 31 Mar 2025
) Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers ... •Keros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interaction.
Edit

KER-065 Data Update (Keros Therapeutics Inc)

Public Technologies 31 Mar 2025
Potential to increase muscle mass, decrease fat mass and improve BMD, based on preclinical data and prior experience with ActRIIB-Fc and Keros molecules ... Keros Therapeutics Inc published this content ...
  • 1
×